PARSIPPANY, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (NASDAQ: EMBC) have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2023 to stockholders of record at the close of business on May 29, 2023.
About embecta
embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
| Contacts: | |
| Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$13.35 |
| Daily Change: | -0.03 -0.22 |
| Daily Volume: | 293,613 |
| Market Cap: | US$780.840M |
August 08, 2025 February 06, 2025 September 03, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
